Europe Pharmacovigilance Market By Service provider (In-house, Contract Outsourcing), By Product Life Cycle (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), By Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), By Process Flow (Case Data Management, Signal Detection, Risk Management System), By Therapeutic Area (
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationEurope Pharmacovigilance Market By Service provider (In-house, Contract Outsourcing), By Product Life Cycle (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), By Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), By Process Flow (Case Data Management, Signal Detection, Risk Management System), By Therapeutic Area (
Europe pharmacovigilance market is anticipated to witness robust growth during the forecast period, 2024-2028. The rising concerns regarding drug safety as well as increase in adverse drug reactions (ADR) and drug toxicity are likely to bolster the growth of the market. Increasing acceptance of personalized medicine is also a key factor for the growth of the market. Moreover, stringent regulations towards drug safety and approval are creating the need for pharmacovigilance services in the region. The rise in prevalence of infectious and chronic diseases are leading to increase the consumption of pharmaceutical drugs as well as the drug development rates, which, in turn, is facilitating the growth of the market. In addition, increasing trend of outsourcing pharmacovigilance services is also a contributing factor which is propelling the market’s growth.
According to World Health Organization, pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. The aim of pharmacovigilance is to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.
Increasing Prevalence of Chronic Conditions
According to the World Health Organisation (WHO), there are around 60 million people with diabetes in the Europe, out of which 10.3% are men and 9.6% are women aged 25 years and over.
Increasing Pharmacovigilance Outsourcing Service
Pharmacovigilance outsourcing is a practice conducted by pharmaceutical or drug manufacturing companies in which drug safety processes are given to third party entity. There is a rapid rise in the adoption of pharmacovigilance outsourcing services, which in turn, is expected to augment the growth of the market. This rapid rise is due to the cost reduction, time constraints, facilities, and flexibility provided to a drug manufacturer. These outsourcing practices also enables to customize as per the requirements, which increase the speed of the evaluation process. Therefore, the rising demand for the pharmacovigilance outsourcing practice by several drug manufacturers are anticipated to drive the growth of the market.
Market Segmentation
Europe pharmacovigilance market is segmented into service provider, product life cycle, type, process flow, therapeutic area,
Market Players
Accenture PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb SARL, Clinquest Group B.V., F Hoffmann-La Roche AG, Foresight Group International AG, ICON PLC, GlaxoSmithKline PLC, Novartis AG and Capgemini SE are some of the leading companies in the market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Service Provider Product Life Cycle Type Process Flow Therapeutic Area End-use Country |
| Country scope | Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece |
| Key companies profiled | Accenture PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb SARL, Clinquest Group B.V., F Hoffmann-La Roche AG, Foresight Group International AG, ICON PLC, GlaxoSmithKline PLC, Novartis AG and Capgemini SE. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy